2014 was a monumental year for the US legal cannabis market. 25 states and Washington D.C. now have some measure of medical or adult-use legislation, creating a market that is estimated to grow to over $10BN by 2018 (Arcview Market Research, 2014).
If you work in the pharmaceutical industry, you know that compliance with FDA rules on promotion is crucial to keeping your business in business. A mere allegation of non-compliance from FDA can have a profound impact on business, both directly (e.g., leading to a drop in sales or stock price) and indirectly (e.g., diverting precious resources to work on a response to the letter). In this article we explore recent FDA enforcement trends related to promotion of pharmaceutical products, and discuss the actions you can take to keep your promotion from getting your company the wrong kind of attention.